Strategic Vision: A Global Pharma Company

Evolving our Generic Portfolio and Pipeline by timing of material contribution 告 Injectables Robust suite of depot, liposomal, peptide and iron injectable products in development LUPIN Inhalation Scaling our early yet meaningful launches while advancing our robust pipeline of MDIs, DPIs, and SMIS Biosimilars ® Commercial momentum ex-US and evolving commercial capabilities in the US backed by exceptional R&D capabilities Women's Health Evolving internal LARC platforms and portfolio 15

View entire presentation